SMi presents Europe's leading 10th annual conference and exhibition: Pre-Filled Syringes Europe 2018

SMi Group17 - 18 January 2018, London, UK.
Join the calendar event highlight for the medical device industry at Europe's leading 10th annual conference and exhibition on Pre-Filled Syringes when it returns to Central London on 17th and 18th January 2018. Pre-Filled Syringes Europe will once again provide a perfect platform to discuss new advancements and showcase the latest innovations to keep you at the forefront of a dynamic and booming market.

Building on the success of its sell-out global 2017 PFS series of events which saw 100+ attendees join shows in London, Boston and San Diego, the agenda for Pre-Filled Syringes Europe 2018 has been carefully tailored to arm you with the key requirements and tools to adapt to an ever-changing medical landscape in areas that are critical to those working within parenteral drug delivery and injectable devices.

Featured Speakers:

  • Alphons Fakler, Group Head Risk Management, Novartis Pharma
  • Bettine Boltres, Technical Account Manager, West Pharmaceutical Services
  • Elizabeth Baker, Group Manager Licensing Division, MHRA
  • Marcel Mueller, Device Project Leader, Novartis
  • Cedric Gysel, Staff Device Engineer, Janssen
  • Carsten Worsoe, Principal Scientist, CMC Analytical Support, Novo Nordisk
  • Vikas Jaitely, Senior Manager CMC Regulatory Intelligence and Pharmaceutical Science, Merck
  • Susanne Joerg, Head of Formulation Development, Lonza
  • Orla Downes, Head of Business Development Unit, Barts Health Pharmaceuticals
  • Barry Knight, Device Program Lead, UCB Celltech
  • Sudeshna Dutta Ray, Senior Engineer, Advanced Device Technology and Innovation, Amgen
  • Alexander Jung, Senior Manager, Technology and Innovation, Drug Delivery and Devices, Boehringer Ingelheim
  • Christian Dechant, Primary Packaging Director, Boehringer Ingelheim

Sponsors include: Früh Verpackungstechnik Ag, Mitsubishi Gas Chemical, Nemera, Panasonic, West Pharmaceutical Services, Worrell and more

Key Topics for 2018:

  • Engage with the latest regulatory updates and guidelines for ultimate product compliance and efficiency
  • Discuss the emerging hot topic of combination products and benchmark against other industry-leaders
  • Participate in the increased focus towards digital connectivity and smart devices for improved patient adherence
  • Follow approaches to human factors and end-user engagement from formulation to after-market development
  • Witness the latest insights into the broader market trends of increased biologics attention and how to address these challenges head on

This event will sell-out. For further information and to register, please visit:
http://www.pre-filled-syringes.com/wpn

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...